Geert D’Haens

Research interests

Publications

• Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2212728

• IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

  Nature Reviews Gastroenterology & Hepatology · 2023 · https://doi.org/10.1038/s41575-023-00768-1

• Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00061-2

• Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00581-5

• Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00467-6

• Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)00466-4

• Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study

  Gastroenterology · 2022 · https://doi.org/10.1053/j.gastro.2022.01.047

• Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease

  Nature Reviews Gastroenterology & Hepatology · 2022 · https://doi.org/10.1038/s41575-021-00574-7

• Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

  Gastroenterology · 2021 · https://doi.org/10.1053/j.gastro.2020.10.065

• Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

  Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.02.030

• Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

  Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.01.047

• Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting

  Gastroenterology · 2020 · https://doi.org/10.1053/j.gastro.2020.04.002

• Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

  ˜The œLancet. Gastroenterology & hepatology · 2018 · https://doi.org/10.1016/s2468-1253(18)30233-4

• Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

  Clinical Gastroenterology and Hepatology · 2018 · https://doi.org/10.1016/j.cgh.2018.11.035

• Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)30570-6

• Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)32641-7

• Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

  Gut · 2017 · https://doi.org/10.1136/gutjnl-2016-312735

• Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1606910

• Development of an index to define overall disease severity in IBD

  Gut · 2016 · https://doi.org/10.1136/gutjnl-2016-312648

• The safety of vedolizumab for ulcerative colitis and Crohn's disease

  Gut · 2016 · https://doi.org/10.1136/gutjnl-2015-311079

• Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

  The American Journal of Gastroenterology · 2015 · https://doi.org/10.1038/ajg.2015.233

• Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

  Gastroenterology · 2015 · https://doi.org/10.1053/j.gastro.2015.03.045

• Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease

  Gastroenterology · 2014 · https://doi.org/10.1053/j.gastro.2014.09.015

• A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease

  Gut · 2014 · https://doi.org/10.1136/gutjnl-2013-306709

• Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study

  Gut · 2013 · https://doi.org/10.1136/gutjnl-2012-304258

• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

  Inflammatory Bowel Diseases · 2012 · 10.1002/ibd.22917

• Review article: defining remission in ulcerative colitis

  Alimentary Pharmacology & Therapeutics · 2011 · https://doi.org/10.1111/j.1365-2036.2011.04701.x

• Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

  Gastroenterology · 2011 · 10.1053/j.gastro.2011.10.032

• Development of the Crohnʼs disease digestive damage score, the Lémann score

  Inflammatory Bowel Diseases · 2010 · https://doi.org/10.1002/ibd.21506

• Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa0904492

• The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

  Journal of Crohn s and Colitis · 2009 · 10.1016/j.crohns.2009.09.009

• Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0805019

• Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

  Gastroenterology · 2009 · 10.1053/j.gastro.2009.09.056

• Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial

  Gastroenterology · 2008 · 10.1053/j.gastro.2008.03.004

• Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

  The Lancet · 2008 · 10.1016/s0140-6736(08)60304-9

• Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease

  Gut · 2007 · 10.1136/gut.2006.099978

• A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

  Gastroenterology · 2006 · 10.1053/j.gastro.2006.12.038

• Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

  Gastrointestinal Endoscopy · 2004 · https://doi.org/10.1016/s0016-5107(04)01878-4

• A Simple Classification of Crohnʼs Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998

  Inflammatory Bowel Diseases · 2000 · 10.1097/00054725-200002000-00002

Current projects

No projects listed.